X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare JUBILANT LIFE SCIENCES with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs SANOFI INDIA - Comparison Results

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES SANOFI INDIA JUBILANT LIFE SCIENCES/
SANOFI INDIA
 
P/E (TTM) x 17.1 39.9 42.7% View Chart
P/BV x 4.5 8.6 52.1% View Chart
Dividend Yield % 0.4 1.0 38.7%  

Financials

 JUBILANT LIFE SCIENCES   SANOFI INDIA
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-14
SANOFI INDIA
Dec-16
JUBILANT LIFE SCIENCES/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1874,560 4.1%   
Low Rs654,400 1.5%   
Sales per share (Unadj.) Rs364.31,028.5 35.4%  
Earnings per share (Unadj.) Rs6.8129.0 5.3%  
Cash flow per share (Unadj.) Rs24.5186.0 13.2%  
Dividends per share (Unadj.) Rs3.0068.00 4.4%  
Dividend yield (eoy) %2.41.5 156.9%  
Book value per share (Unadj.) Rs164.9753.6 21.9%  
Shares outstanding (eoy) m159.2823.03 691.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.34.4 7.9%   
Avg P/E ratio x18.434.7 53.0%  
P/CF ratio (eoy) x5.124.1 21.3%  
Price / Book Value ratio x0.85.9 12.8%  
Dividend payout %43.852.7 83.1%   
Avg Mkt Cap Rs m20,061103,174 19.4%   
No. of employees `0006.23.6 170.7%   
Total wages/salary Rs m11,0523,592 307.7%   
Avg. sales/employee Rs Th9,383.06,537.7 143.5%   
Avg. wages/employee Rs Th1,786.9991.4 180.2%   
Avg. net profit/employee Rs Th176.3819.8 21.5%   
INCOME DATA
Net Sales Rs m58,03423,686 245.0%  
Other income Rs m191708 26.9%   
Total revenues Rs m58,22424,394 238.7%   
Gross profit Rs m5,7865,281 109.6%  
Depreciation Rs m2,8121,313 214.1%   
Interest Rs m3,23715 21,581.3%   
Profit before tax Rs m-724,661 -1.5%   
Minority Interest Rs m-2860-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m2,1450-   
Tax Rs m6961,691 41.2%   
Profit after tax Rs m1,0902,970 36.7%  
Gross profit margin %10.022.3 44.7%  
Effective tax rate %-965.936.3 -2,662.3%   
Net profit margin %1.912.5 15.0%  
BALANCE SHEET DATA
Current assets Rs m29,28015,673 186.8%   
Current liabilities Rs m38,9126,678 582.7%   
Net working cap to sales %-16.638.0 -43.7%  
Current ratio x0.82.3 32.1%  
Inventory Days Days8476 111.0%  
Debtors Days Days5122 227.1%  
Net fixed assets Rs m55,7128,098 688.0%   
Share capital Rs m155230 67.1%   
"Free" reserves Rs m20,96817,088 122.7%   
Net worth Rs m26,26517,356 151.3%   
Long term debt Rs m17,1690-   
Total assets Rs m88,60625,400 348.8%  
Interest coverage x1.0311.7 0.3%   
Debt to equity ratio x0.70-  
Sales to assets ratio x0.70.9 70.2%   
Return on assets %4.911.8 41.6%  
Return on equity %4.217.1 24.3%  
Return on capital %11.626.9 42.9%  
Exports to sales %37.824.5 154.3%   
Imports to sales %16.528.0 58.9%   
Exports (fob) Rs m21,9335,801 378.1%   
Imports (cif) Rs m9,5676,627 144.4%   
Fx inflow Rs m22,0047,145 308.0%   
Fx outflow Rs m11,7496,846 171.6%   
Net fx Rs m10,255299 3,429.8%   
CASH FLOW
From Operations Rs m8,0263,226 248.8%  
From Investments Rs m-1,744-1,555 112.2%  
From Financial Activity Rs m-4,447-1,818 244.6%  
Net Cashflow Rs m1,834-147 -1,247.9%  

Share Holding

Indian Promoters % 45.6 0.0 -  
Foreign collaborators % 3.5 60.4 5.8%  
Indian inst/Mut Fund % 8.7 14.4 60.4%  
FIIs % 21.2 14.6 145.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 10.5 201.0%  
Shareholders   23,815 15,184 156.8%  
Pledged promoter(s) holding % 15.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   PANACEA BIOTECH  BIOCON LTD  J.B.CHEMICALS  NATCO PHARMA  DIVIS LABORATORIES  

Compare JUBILANT LIFE SCIENCES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY19); Net Profit Up 39.4% (Quarterly Result Update)

Jul 31, 2018 | Updated on Jul 31, 2018

For the quarter ended June 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 39.4% YoY). Sales on the other hand came in at Rs 21 bn (up 30.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY18); Net Profit Up 37.5% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, SANOFI INDIA has posted a net profit of Rs 825 m (up 37.5% YoY). Sales on the other hand came in at Rs 6 bn (up 11.7% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY18); Net Profit Up 1.4% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 1.4% YoY). Sales on the other hand came in at Rs 23 bn (up 37.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Sep 21, 2018 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES 5-YR ANALYSIS

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS